Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$8 Mln
P/E Ratio
--
P/B Ratio
0.56
Industry P/E
--
Debt to Equity
0.77
ROE
-0.74 %
ROCE
-51.32 %
Div. Yield
0 %
Book Value
1.55
EPS
-1.49
CFO
$-13.37 Mln
EBITDA
$-25.87 Mln
Net Profit
$-38.53 Mln
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
---|---|---|---|---|---|---|---|
Ainos Inc (AIMD)
| 19.52 | 1.11 | -31.79 | -48.10 | -74.34 | -50.64 | -28.22 |
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
2024
|
2023
|
|
---|---|---|
Ainos Inc (AIMD)
| -77.48 | -33.87 |
S&P Small-Cap 600
| 7.01 | 13.89 |
BSE Sensex
| 8.10 | 18.74 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
---|---|---|---|---|
37.43 | 10,135.98 | 20.78 | 23.13 | |
298.55 | 8,668.61 | 21.55 | 58.42 | |
27.22 | 9,559.25 | -- | -28.77 | |
106.73 | 10,030.35 | 30.81 | 14.16 |
Ainos, Inc., a healthcare company, focuses on the development of novel point-of-care testing therapeutics based on very low-dose interferon alpha and synthetic RNA-driven preventative medicine. The company provides COVID-19 antigen rapid test kit and... VELDONA pet supplement, a health issues in dogs and cats, including skin, gum, emotion, discomfort caused by allergies, eye, and weight-related issues. It offers VELDONA human and animal drugs, a human drug pipeline includes treatments for oral warts in HIV-seropositive patients, Sjögren's syndrome, common cold, and influenza; VOC POCT " Ainos Flora designed to offer a quick, non-invasive test for female vaginal health and common STIs; and VOC platform " NISD co-development sensing platform based on AI Nose. In addition, the company provides VOC POCT " Ainos Pen, a cloud-connected, multi-purpose, portable breath analyzer that is intended to monitor health conditions within minutes; VOC POCT " CHS430 provide non-invasive testing for ventilator-associated pneumonia within few minutes, as compared to current standard of care invasive culture tests that typically take more than two days to provide results; and Synthetic RNA develops a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California. Address: 8880 Rio San Diego Drive, San Diego, CA, United States, 92108 Read more
Chairman of Board, President & CEO
Mr. Chun-Hsien Tsai
Chairman of Board, President & CEO
Mr. Chun-Hsien Tsai
Headquarters
San Diego, CA
Website
The total asset value of Ainos Inc (AIMD) stood at $ 29 Mln as on 31-Dec-24
The share price of Ainos Inc (AIMD) is $0.55 (NASDAQ) as of 25-Apr-2025 16:14 EDT. Ainos Inc (AIMD) has given a return of -74.34% in the last 3 years.
Ainos Inc (AIMD) has a market capitalisation of $ 8 Mln as on 24-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Ainos Inc (AIMD) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Ainos Inc (AIMD) and enter the required number of quantities and click on buy to purchase the shares of Ainos Inc (AIMD).
Ainos, Inc., a healthcare company, focuses on the development of novel point-of-care testing therapeutics based on very low-dose interferon alpha and synthetic RNA-driven preventative medicine. The company provides COVID-19 antigen rapid test kit and VELDONA pet supplement, a health issues in dogs and cats, including skin, gum, emotion, discomfort caused by allergies, eye, and weight-related issues. It offers VELDONA human and animal drugs, a human drug pipeline includes treatments for oral warts in HIV-seropositive patients, Sjögren's syndrome, common cold, and influenza; VOC POCT " Ainos Flora designed to offer a quick, non-invasive test for female vaginal health and common STIs; and VOC platform " NISD co-development sensing platform based on AI Nose. In addition, the company provides VOC POCT " Ainos Pen, a cloud-connected, multi-purpose, portable breath analyzer that is intended to monitor health conditions within minutes; VOC POCT " CHS430 provide non-invasive testing for ventilator-associated pneumonia within few minutes, as compared to current standard of care invasive culture tests that typically take more than two days to provide results; and Synthetic RNA develops a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California. Address: 8880 Rio San Diego Drive, San Diego, CA, United States, 92108
The CEO & director of Mr. Chun-Hsien Tsai. is Ainos Inc (AIMD), and CFO & Sr. VP is Mr. Chun-Hsien Tsai.
There is no promoter pledging in Ainos Inc (AIMD).
Some of the close peers are:
Company | Market Cap($ Mln) |
---|---|
1,014
|
|
1,003
|
|
956
|
|
867
|
Ainos Inc (AIMD) | Ratios |
---|---|
Return on equity(%)
|
-74.38
|
Operating margin(%)
|
-68724.46
|
Net Margin(%)
|
-71702.26
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Ainos Inc (AIMD) was $0 Mln.